BioSpace News Archive

Angel ’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program Strategic collaboration gives Corvus 49.7% equity stake and provides an opportunity to accelerate the development of the Corvus pipeline in China and globally Angel launches with $41 million financing backed by local investor group which includes three prominent biopharmaceutical companies Corvus hosting c onference c all t o

Q-State Biosciences Announces the Appointment of Biopharma Veteran Paul Medeiros as President and Chief Executive Officer CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Q-State Biosciences (“Q-State”), a precision therapeutics company developing treatments for diseases associated with electrically excitable cells, announced today the appointment of Paul Medeiros as President and Chief Executive Officer of the company. With nearly 25 years of global executive pharmac

FH Ortho, Inc. a long standing, well respected manufacturer of innovative orthopedic implantable devices is pleased to announce the FDA clearance of its e-Ortho planning software that will further expand the Arrow Prime Shoulder Arthroplasty platform. Jean-Marc Idier, President and CEO of FH Ortho, stated, “e-Ortho demonstrates our commitment to advancements in shoulder arthroplasty by providing our customers with increased value through a means of

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed John F. Crowley to its Board of Directors. Mr. Crowley is a well-established leader in biotech and pharmaceuticals and a visionary advocate for the advancement of treatments for people living with rare diseases. He joins Intellia’s board during a pivota

Real-World Population Representative of P atients Enrolled in GALACTIC-HF I ndicate a H igh- N eed, H igh- R isk P opulation with Heart Failure New Results from COSMIC-HF Show Treatment with Omecamtiv Mecarbil Associated with Improved Right Ventricular Function SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the Heart Failure Society of America (HFSA) Virtual An

-- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --

Hepion Pharmaceuticals, Inc. today announced the rollout of a proprietary artificial intelligence (“AI”), machine learning platform called, AI-POWR™.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

-- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced the advancement of its collaboration with Georg

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate the combination of Zenith’s epigenetic therapy – BET inhibitor ZEN-3694 – with i